A leading cause of blindness in the world, it is a progressive optic neuropathy often associated with increased intraocular pressure and characterized by progressive death of retinal ganglion cells (RGCs).1 The European Glaucoma Society recognizes neuroprotection as an adjuvant treatment option in glaucoma2 and there is evidence that coenzyme Q1O has a potential retinal neuroprotective action.1,4-6 Topical CoQ1O has proved to be an effective therapy preventing RGC apoptosis and losing glaucoma-related models.5* This is due to its anti-apoptotic, antioxidant and bioenergetic properties.3,7